Indoco Remedies (Small Cap - High Growth) Share Target 2025, 2026 To 2035
|
Indoco Remedies Limited |
|||
|
Price: ₹341.00 (+2.48%) | ||
| 52 Week Low: ₹286.60 52 Week High: ₹414.00 |
|||
| Market Capital: 2,841.06 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Indoco Remedies Share Price Target For 2025
- 1.1.1: Indoco Remedies Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Indoco Remedies Share Price Target For 2026
- 1.2.1: Indoco Remedies Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Indoco Remedies Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Indoco Remedies Brief Company Overview
- 4: Indoco Remedies Financial Performance
- 4.0.1: Is Indoco Remedies A Good Buy For Long Term?
Indoco Remedies, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 56.5% returns in 5-year with 1.8% profit margin, making it a High Growth stock.
To predict the Indoco Remedies's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Indoco Remedies Share Price Target For 2025
The line chart displays the monthly closing prices of Indoco Remedies with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Indoco Remedies shares in 2025, see the table below.
Indoco Remedies Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 363.52 (+6.6%) | Price Action: 30 Jan 2024 Low |
| 2025 Target 2 | 359.74 (+5.49%) | Price Action: 29 Aug 2024 Low |
| 2025 Target 1 | 356.15 (+4.44%) | Price Action: 21 Feb 2024 Low |
| Current Price | 341.00 | Indoco Remedies's share price as of 21 Jan 2025 |
| Stop Loss 1 | 334.05 (-2.04%) | Price Action: 01 Jan 2025 High |
| Stop Loss 2 | 330.65 (-3.04%) | Price Action: 25 Apr 2024 High |
| Stop Loss 3 | 327.17 (-4.05%) | Price Action: 19 Apr 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Indoco Remedies is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹333.06 serves as the nearest technical reference point.
Historical Returns: 3-month: +9.86% | 6-month: +2.99% | 1-year: -8.02%
Indoco Remedies Share Price Target For 2026
The line chart displays the monthly closing prices of Indoco Remedies with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Indoco Remedies shares in 2026, see the table below.
Indoco Remedies Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 435.7 (+27.77%) | Price Action: Chart |
| 2026 Target 2 | 427.58 (+25.39%) | Price Action: Chart |
| 2026 Target 1 | 423.35 (+24.14%) | Fibonacci Extension Level 64.90% |
| Current Price | 341.00 | Indoco Remedies's share price as of 21 Jan 2025 |
| Stop Loss 1 | 322.0 (-5.58%) | Price Action: 22 Oct 2024 Low |
| Stop Loss 2 | 318.75 (-6.53%) | Price Action: 26 Jul 2024 Low |
| Stop Loss 3 | 315.5 (-7.48%) | Price Action: 01 Nov 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Indoco Remedies is currently trading at 42.7% of its 52-week range (₹286.6 - ₹414).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: -8.02% | 3-year: -10.41% | 5-year: +56.52%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Indoco Remedies Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹341.00 | ||
| 2025 | ₹388.53 | +13.93% | ₹394.36 |
| 2026 | ₹392.21 | +0.94% | ₹398.09 |
| 2027 | ₹365.25 | -6.87% | ₹370.73 |
| 2028 | ₹392.39 | +7.43% | ₹398.28 |
| 2029 | ₹414.17 | +5.55% | ₹420.38 |
| 2030 | ₹431.05 | +4.07% | ₹437.52 |
| 2031 | ₹464.49 | +7.75% | ₹471.46 |
| 2032 | ₹501.45 | +7.95% | ₹508.97 |
| 2033 | ₹542.22 | +8.13% | ₹550.35 |
| 2034 | ₹584.60 | +7.81% | ₹593.37 |
| 2035 | ₹597.41 | +2.19% | ₹606.37 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Indoco Remedies Brief Company Overview
Indoco Remedies Limited: A Reputable Pharmaceutical Powerhouse Established in 1945, Indoco Remedies Limited is an esteemed pharmaceutical company headquartered in Mumbai, India. With a global presence, the company has carved a niche for itself by manufacturing,...
marketing, and selling a diverse range of formulations and active pharmaceutical ingredients. Indoco Remedies boasts an extensive product portfolio that caters to various therapeutic segments. Their offerings include stomatological, gastrointestinal, respiratory, anti-infective, vitamin/mineral/nutrient, ophthal/ontological, antifungal, hormonal, dermatology, urological, anti-diabetic, gynaecological, lifestyle management, pain/analgesic, and cardiac products. Beyond its core pharmaceutical business, Indoco Remedies also provides analytical services, architectural design, and contract research and manufacturing services to various industries. Commitment to Excellence: Indoco Remedies is committed to delivering high-quality products and services while adhering to stringent regulatory standards. The company's focus on innovation and research has propelled it to become a trusted name in the pharmaceutical industry.Indoco Remedies Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,841.06 Crore | Market valuation of Indoco Remedies's shares. |
| Revenue (TTM) | 1,773.21 Crore | Total revenue generated by Indoco Remedies over the past twelve months. |
| Net Income (TTM) | +32.06 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +2.64% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +1.8% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-10.19% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
76.63 | Company's total debt divided by total shareholder equity. |
| Total Debt | 834.4 Crore | Sum of Indoco Remedies's current & long-term financial obligations. |
| Total Cash | 41.73 Crore | Total amount of liquid funds available to Indoco Remedies. |
| Beta | 0.44 | Beta is less than 1 indicating that the Indoco Remedies's price is less volatile than the market. |
Is Indoco Remedies A Good Buy For Long Term?
Indoco Remedies, a small-cap stock with a market capitalization of ₹2,841.06 crore, presents a mixed picture for long-term investors. While its 5-year return of 46.22% is encouraging, recent performance shows a concerning downward trend: -20.05% YTD and a negative profit margin of 1.8%. The substantial debt of ₹834.4 crore against a meager cash balance of ₹41.73 crore raises significant financial risk. Considering these factors, Indoco Remedies is not a good buy for the long term at this time. Further analysis and a more stable financial outlook are needed before considering investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
